This is the profile of Dr Roger Aston our new Board member
Dr Roger Aston is one of the most experienced and commercially astute people in drug commercialisation in Australia. Roger brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the United Kingdom, Asia-Pacific and Australia. Roger has held executive, non-executive director or chairman positions on a number of boards including Peptech Limited (Arana), Cambridge Antibody Technology Limited, Clinuvel Limited, Halcygen Limited, Cambridge Drug Discovery, and pSivida Limited. He started his career at major pharmaceutical company Wellcome (now Glaxo Smith Kline) and has also worked for QinetiQ Limited. Roger also served on the federal government's IRD board sub-committee for biologicals. Roger was formerly CEO of Mayne Pharma Group Limited and currently is a director and CEO of Pitney Pharmaceuticals Pty Ltd, Chairman of BioLife Limited, Chairman of Immuron Limited, Director of IDT Limited, Chairman of Cynata Limited and Chairman elect of NeuroDiscovery Limited
CZD Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
